RxDoctor Payments Data

Joel Pengson, MD

Internal Medicine · Moreno Valley, CANPI 1720018237

Payments from drug & device makers

$28,529in general payments, 2019–2025

Across 673 payments — averaging $42.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Corium, LLC$3K
  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Amarin Pharma, Inc.$1K
  • Merck$1K
  • AstraZeneca$1K
  • plus $8K from 49 others

What the payments were for

  • Consulting fees$9403%
  • Speaking & faculty fees$12,64044%
  • Travel & lodging$1,0974%
  • Food & beverage$13,73648%
  • Education$1170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,529 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$599,074
Medicare patients
384
Services billed
9,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$149,214
EliquisApixaban299$139,195
JardianceEmpagliflozin181$138,177
KerendiaFinerenone140$109,237
OtezlaApremilast33$96,042
SantylCollagenase Clostridium Hist.23$92,573
XareltoRivaroxaban198$68,359
MounjaroTirzepatide55$60,788
EntrestoSacubitril/Valsartan73$59,474
ProcritEpoetin Alfa33$50,959
FarxigaDapagliflozin Propanediol61$46,579
VascepaIcosapent Ethyl92$44,443
XifaxanRifaximin29$43,836
Tresiba Flextouch U-200Insulin Degludec64$41,503
TrulicityDulaglutide19$33,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$806$149,214150 claims
PfizerEliquis$89$139,195299 claims
Boehringer IngelheimJardiance$642$138,177181 claims
Johnson & JohnsonXarelto, Procrit$80$119,318231 claims
BayerKerendia$600$109,237140 claims
AmgenOtezla$491$96,04233 claims
Lilly USA, LLCMounjaro, Trulicity$635$94,57874 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Airsupra$1,084$82,748127 claims
NovartisEntresto$647$59,47473 claims
MerckVerquvo, Januvia, Steglatro$1,092$52,57292 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$65$43,83629 claims
AbbVieCreon, Linzess$12,783$24,78024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Moreno Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →